Already a member? Login to access this report free.
Report Highlights
The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.
Report Includes
- 55 data tables and 70 additional tables
- An updated overview and in-depth analysis of the global influenza market
- Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
- Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
- Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
- Analysis of the market opportunities through the Porter’s Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
- Insight into the influenza industry structure, government regulations, and key development issues
- Analysis of the key patent grants and IP aspects
- A discussion of the industry’s ESG challenges and practices of the industry
- Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
- Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott
Report Scope
This report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.
Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions—North America, Europe and Asia-Pacific—and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.
The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.
For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $8.4 Billion | ||||||||||||||||
| Market size forecast | $12.8 Billion | ||||||||||||||||
| Growth rate | CAGR of 7.2% for the forecast period of 2024-2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Product Segment, and Region | ||||||||||||||||
| Regions covered | North America, Asia-Pacific, Europe, Rest of the World | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, Australia, South America, and Middle East and Africa | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.
Report Includes
- 25 data tables and 77 additional tables
- An overview of the global influenza market
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Identification of segments with high growth potential and their future applications
- Discussion on the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus, human metapneumovirus (hMPV) and others
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including Alere, MedImmune, Cepheid, GlaxoSmithKline and Qiagen.
Report Highlights
The global influenza market reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.
Report Highlights
The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.
Report Includes
- An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 and 2018.
- Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
- Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
- Comprehensive company profiles of major players.
Report Highlights
- Overall sales in the global influenza market were worth $5.3 billion in 2007, which declined to $3.7 billion in 2008, then increased to an estimated $5.5 billion in 2009. By 2014, it is projected to increase to $6.3 billion, for a 5-year CAGR of 2.7%.
- The largest segment of the market, vaccines, was valued at $2.8 billion in 2008; this is expected to increase to $3.2 billion in 2009, and is projected to reach $4.2 billion in 2014, for a 5-year CAGR of 5.6%.
- Sales in the therapeutics market amounted to $701 million in 2008, increased to an estimated $2.1 billion in 2009, and are expected to fall to $1.9 billion in 2014, for a 5-year CAGR of -2.4%.
Report Highlights
- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
- The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
- The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
- The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
Related Reports
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Global Markets and Technologies for Pandemic Control
The global infectious diseases market reached $238.5 billion in 2022 and should reach $300.8 billion by 2027, with a compound annual growth rate (CAGR) of 4.7% during the forecast period of 2022-2027.
Nasal Vaccines: Global Markets and Pipeline Analysis
The global market for nasal vaccines is estimated to increase from $383.8 million in 2022 to reach $568.1 million by 2027, at a compound annual growth rate (CAGR) of 8.2% from 2022 through 2027.
Pediatric Vaccines: Global Markets
The global pediatric vaccines market should reach $34.5 billion by 2022 and more than $50.2 billion by 2027, with a compound annual growth rate (CAGR) of 7.8% during the forecast period of 2022-2027.
Recent Reports
Over-the-Counter (OTC) Drugs, and Vitamins & Dietary Supplements: Global Markets
The global market for over-the- counter (OTC) drugs, vitamins and dietary supplements is expected to grow from $276.9 billion in 2025 and is projected to reach $371.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2025 to 2030.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
The Global Influenza Market
The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.
Liver Disease Treatments: The Global Market
The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Global Diabetic Care Devices Market
The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.
2024 Medical Devices Research Review
The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.
Global Lithium-ion Battery Market
The global market for lithium-ion battery (LIB) is expected to grow from $117.8 billion in 2024 and is projected to reach $221.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.
Generative AI: Global Markets
The global market for generative AI was valued at $15.4 billion in 2023. It is projected to grow from $20.8 billion in 2024 to $94.4 billion by 2029, at a compound annual growth rate (CAGR) of 35.3% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More